Abstract
Human medicines European public assessment report (EPAR): Vyxeos liposomal (previously known as Vyxeos), daunorubicin / cytarabine, Leukemia, Myeloid, Acute, Date of authorisation: 23/08/2018, Revision: 2, Status: Authorised
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
